- Home
- NA vs MXCT Comparison
NA vs MXCT Comparison
Compare NA & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | MXCT |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | China | United States |
| Employees | N/A | 114 |
| Industry | Semiconductors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 81.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NA | MXCT |
|---|---|---|
| Price | $3.00 | $0.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 55.2K | ★ 950.0K |
| Earning Date | 03-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,627,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.75 | $0.64 |
| 52 Week High | $31.48 | $3.15 |
Technical Indicators
Market Signals| Indicator | NA | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 40.64 |
| Support Level | $2.86 | $0.75 |
| Resistance Level | $3.42 | $0.87 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 39.05 | 19.79 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.